echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The dawn of ending the new crown is dawning

    The dawn of ending the new crown is dawning

    • Last Update: 2021-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    BioNTech and Pfizer today released top-level analysis data for the full results of their mRNA new crown vaccine, BNT162b2, following a mid-term clinical analysis of phase III.
    analysis showed that the vaccine reached the end of all phase III clinical trials, with 162 of the 170 infections occurring in the placebo group and 8 in the vaccine group, with a protective rate of 95% and similar rates for people over 65 years of age.
    9 of the 10 serious cases occurred in the placebo group and one in the vaccine group.
    adverse reactions were mainly fatigue and headache, with the rate of occurrence above three accounting for 3.8% and 2%, respectively.
    that the data is ready to beat the new crown, Pfizer and BNTX are preparing to apply this week for emergency use of the vaccine.
    are expected to produce 50m this year and 1.3bn next year.
    analysis of drug sources this data is better than the interim analysis results, mainly because the data published at that time is more vague, said to be more than 90%.
    if from a strict scientific terminology analyst means that the lower line of the confidence interval is 90%, but no one came out to clarify at the time.
    another new mRNA crown vaccine, Moderna, announced Monday that its similar product, mRNA-1273, showed a 95 percent protection rate and no adverse reactions as an obstacle based on data analysis of 95 infections.
    the results of these three analyses, reliably indicating that the vaccine is safe and effective.
    BNT162b2 also induces a more obvious T-cell response in phase I clinical trials in addition to antibodies, the efficacy of these two products is now very similar.
    of course, one of the major differences between the two products is the preservation conditions.
    BNT162b2 requires -80 degrees preservation and mRNA-1273 requires -20 degrees, which can have a significant impact on large-scale use.
    the main problem is not market competition, but insufficient capacity, at least in the early two products sales speed limit steps are production.
    these two vaccines will obviously have an immediate and profound impact on the new crown control.
    despite the pharmaceutical industry's efforts to develop new coronary drugs, there are currently no drugs other than dexamisson that can reduce mortality.
    new crown antibodies are also available through EUA, but only in the early use of a certain effect, and the dose is large and expensive.
    vaccine now requires two stitches, but a one-shot course of treatment is also being tested.
    the time of protection is not yet known, it is expected to protect for at least a few months from observations of a relatively rare recurring infection.
    this also matches the protection time of most vaccines, with the exception of flu vaccines, which require annual fighting.
    we've said before that one of the main uses of vaccines is to break the chain of infection and end large-scale infections even after full use, even if the time limit is limited.
    so these two vaccines are decisive victories against the new crown.
    many politicians have repeatedly claimed that vaccines will be available as soon as this year, the real realization of this goal reflects both the power of science and technology today and some element of luck.
    development of vaccines is often similar to that of new drugs, with an average development time of 8-10 years.
    not all viruses can find a vaccine, and HIV is not yet available.
    so the new crown vaccine will be available 10 months after the virus gene sequence is announced is a huge technical achievement.
    Before this war, mRNA technology was a new technology with no advanced clinical data, and major new technology platforms such as antibodies, gene therapy, RNAi to find a breakthrough will take more than a decade or two, and it cannot be said that the new crown in the prescribed time, prescribed indications to achieve a breakthrough.
    in fact, most new technologies start with relatively easy rare diseases, and the rush of the mRNA vaccine, the first phase iii of the clinic, is an extreme example of 30,000 to 40,000 people.
    many of the adverse scenarios predicted at the beginning of the year did not occur, these concerns are by no way superfluous.
    mRNA is complex, the immune system is complex, the new coronavirus is complex, thanks God these two vaccines worked so damned well.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.